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Epidemiological associations linking between obstructive sleep apnea and poorer 
solid malignant tumor outcomes have recently emerged. Putative pathways proposed 
to explain that these associations have included enhanced hypoxia inducible factor 
(HIF)-1α and vascular endothelial growth factor (VEGF) cell expression in the tumor and 
altered immune functions via intermittent hypoxia (IH). Here, we examined relationships 
between HIF-1α and VEGF expression and nocturnal IH in cutaneous melanoma (CM) 
tumor samples. Prospectively recruited patients with CM tumor samples were included 
and underwent overnight polygraphy. General clinical features, apnea–hypopnea index 
(AHI), desaturation index (DI4%), and CM characteristics were recorded. Histochemical 
assessments of VEGF and HIF-1α were performed, and the percentage of positive cells 
(0, <25, 25–50, 51–75, >75%) was blindly tabulated for VEGF expression, and as 0, 
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0–5.9, 6.0–10.0, >10.0% for HIF-1α expression, respectively. Cases with HIF-1α expres-
sion >6% (high expression) were compared with those <6%, and VEGF expression 
>75% of cells was compared with those with <75%. 376 patients were included. High 
expression of VEGF and HIF-1α were seen in 88.8 and 4.2% of samples, respectively. 
High expression of VEGF was only associated with increasing age. However, high 
expression of HIF-1α was significantly associated with age, Breslow index, AHI, and 
DI4%. Logistic regression showed that DI4% [OR 1.03 (95% CI: 1.01–1.06)] and Breslow 
index [OR 1.28 (95% CI: 1.18–1.46)], but not AHI, remained independently associated 
with the presence of high HIF-1α expression. Thus, IH emerges as an independent risk 
factor for higher HIF-1α expression in CM tumors and is inferentially linked to worse 
clinical CM prognostic indicators.
Keywords: melanoma, intermittent hypoxia, obstructive sleep apnea, hypoxia-inducible factor, vascular 
endothelial growth factor
inTrODUcTiOn
Cutaneous melanoma (CM) is a very aggressive type of skin 
cancer that is not only fraught with a high mortality rate, but is 
also a cancer type whose incidence has continued to increase over 
the last several decades (1). In an effort to identify tumors with 
more aggressive properties, several investigators have postulated 
that the high proliferative rates of CM could induce the presence 
of episodic intra-tumoral hypoxia, which in turn could foster 
alterations in melanoma malignant cells to promote invasion and 
metastasis, as well as resistance to chemotherapy (2–4).
Since intermittent hypoxia (IH)-induced alterations in tumor 
malignancy are driven, at least in part, by the transcriptional 
activity of hypoxia inducible factor-1α (HIF-1α) pathways 
(5–7), it is not surprising that many of the HIF-1α genes that 
are involved in regulation of cellular bioenergetics, angiogenesis, 
and expansion of the vascular supply network exhibit increased 
expression within rapidly proliferating tumors and are, therefore, 
considered as potentially viable reporters of CM aggressive-
ness and poor outcomes (8, 9). In addition, one of the major 
genes regulated by HIF-1α transcriptional activity is vascular 
endothelial growth factor (VEGF), a major regulator of the 
number of capillaries within a tissue (10, 11) and is also active 
in a vasculogenic mimicry capacity (12). Studies exploring the 
expression HIF-1α and VEGF in CM have, however, resulted in 
somewhat inconsistent results, with a propensity of the findings 
supporting the concept that increased expression of HIF-1α and 
VEGF in CM is associated with tumor staging as well as with 
other prognostic indicators (13–21).
Obstructive sleep apnea (OSA) is a highly prevalent disorder 
characterized by the presence of increased upper airway collaps-
ibility during sleep that leads to either upper airway collapse or 
restricted airflow and consequent periodic hypoxia and hyper-
capnia events, usually terminated by arousal and restoration of 
airflow (22–24). The cyclical hypoxic events that characterize 
OSA have been implicated in a vast array of OSA-associated 
morbidities involving cardiovascular, metabolic, and cognitive 
systems (25–27). In recent years, potential associations between 
OSA and cancer have been reported and primarily ascribed to 
the effects of IH on tumor biology (28–31). In addition, both 
experimental and clinical evidence has indicated that CM is one 
of the more susceptible tumors to the IH patterns that character-
ize OSA (32–34).
Based on aforementioned considerations, we hypothesized 
that semiquantitative assessments of HIF-1α and VEGF immu-
noreactivity in excised CM tumors may be associated with 
typical severity measures of OSA. Hence, the objective of the 
present study was to analyze potential associations between the 
expression of HIF-1α and VEGF and measures of respiratory 
disturbance during sleep in a large prospective series of patients 
suffering from CM.
MaTerials anD MeThODs
Design, setting, and Patients
We conducted a prospective, multicenter study in 29 Spanish 
University Hospitals. Consecutive patients diagnosed with CM by 
the dermatology or oncology departments were eligible for inclu-
sion in this study. Patients were excluded if they had melanoma of 
an unknown primary cause, melanoma in mucosa or melanomas 
“in situ,” respiratory failure, heart failure grades III–IV NYHA, 
pregnancy, or a prior diagnosis of SDB or CPAP treatment. The 
study was approved by the Ethical Committee of each participat-
ing center, and all patients signed the informed consent.
Procedures
All tumors were surgically resected and subjected to clinical 
staging. In addition to standard pathologic assessment in each 
center to establish the diagnosis of CM, all the specimens were re-
evaluated in a melanoma reference center by an expert pathology 
panel whose members were blinded to any of the immunostaining 
findings. For each tumor, the following pathologic features were 
assessed by the panel: Breslow tumor thickness (in millimeter, and 
categorized as ≤1.00, 1.01–2.00, 2.01–4.00, and >4.00), ulcera-
tion (presence vs. absence), tumor mitotic rate (according to “hot 
spot” method and categorized in: >5 vs. ≤5 mitoses/mm2), and 
regression (presence vs. absence). Furthermore, the following 
FigUre 1 | Representative examples of VEGF and HIF-1α expression according to expression levels (low, medium, and high) in melanoma sections.
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clinical characteristics were also documented: tumor location 
(head/neck, upper extremities, trunk, lower extremities, acral), 
age at diagnosis, sex, body mass index (BMI, kg/m2), skin photo-
type, and stage at diagnosis [localized (I–II), loco-regional disease 
(III), and distant metastasis (IV)] by the treating dermatologists 
and institutional pathologists. In addition, the staging of each 
tumor was confirmed by a multi-institutional tumor board that 
was unaware of the immunohistological findings described below. 
Other markers of melanoma aggressiveness, namely, the presence 
of ulceration and regression in biopsy tissue, histologic subtypes 
of melanoma, presence of metastasis, and the invasion of sentinel 
lymph nodes were also documented.
immunohistochemistry
Immunohistochemistry was performed on 4-μm-thick sec-
tions of formalin-fixed, paraffin-embedded melanoma samples. 
Immunostaining was performed on a Leica Bond-III stainer (Leica 
Biosystems, Newcastle, UK) using the Leica Bond Polymer Refine 
Kit (Leica Biosystems). Melanoma samples were stained with a 
1:2 dilution of anti-VEGF prediluted antibody (ab27620, Abcam, 
Cambridge, UK) and with a 1:100 dilution of anti-HIF-1α anti-
body (ab51608, Abcam). The staining results were independently 
analyzed by two expert pathologists who were blinded to the stag-
ing and clinical features of the subjects. VEGF-specific staining 
was scored taking into account both the percentage of positive 
cells (0, <25, 25–50, 51–75, >75%) and expression intensity (low, 
moderate, or high) (Figure 1). HIF-1α-specific nuclear staining 
was scored taking into account the percentage of positive cells 
(0, 0–5, 6–10, >10%) as well as the expression intensity (low, 
moderate, or high) (Figure 1). After the blind scoring of immu-
nohistochemical stains in each tumor was completed, the data 
were tabulated, and are presented accordingly.
sleep study
All patients included in the study underwent a diagnostic 
sleep study by means of respiratory polygraphy, using a device 
validated against polysomnography (Embletta Gold in 37% of 
the patients and Alice PDX in 63% of patients) both validated 
against PSG, and following the Spanish Society of Pneumology 
and Thoracic Surgery Guidelines for OSA diagnosis and treat-
ment. The time span between the initial appointment for sus-
picion of melanoma and the sleep study was always lower than 
6 months. Every sleep study was manually scored by skilled staff. 
All the studies included continuous recording of the oro-nasal 
flow and pressure, respiratory movements, and oxyhemoglobin 
saturation (SpO2). Apnea was defined as complete cessation of 
oro-nasal flow for ≥10 s and was classified as either obstructive 
or central, based on the presence or absence of respiratory efforts. 
Hypopnea was defined as a 30–90% reduction in oro-nasal flow 
for ≥10 s followed by a ≥3% decrease in SpO2, while Tsat90 was 
defined as the percentage of recording time with SpO2 <90%. 
The recording time, desaturation indices at 4% and the mean 
baseline nocturnal, baseline daytime, and minimum nocturnal 
saturation were also recorded. Those tests in which the patients 
claimed to sleep less than 4 h, or in which there were less than 5 h 
of nocturnal recording, were repeated.
TaBle 2 | Sleep characteristics and other comorbidities.
Parameters N (%)
site of sleep study, n (%)
Hospital 110 (29.3%)
Home 266 (70.7%)
Sleep study time, h 7.2 (1.2)
Chronic snoring (at least 3 day/week), n (%) 241 (64.1%)
Number of days/week 3.7 (2.96)
Witnessed apnea, n (%) 75 (19.9%)
Epworth score 6 (3.5)
Epworth ≥ 10 59 (15.7%)
Neck circumference, cm 37.9 (4.5)
Sleep duration, h 7.4 (1.27)
<6 h 77 (20.5%)
6–8 h 239 (63.6%)
>8 h 60 (16%)
Insomnia 30 (8%)
Baseline SpO2 97 (3.3)
Apnea–hypopnea index (AHI), events/h 14.5 (16.2)
AHI ≥ 5 247 (66%)
AHI ≥ 15 128 (34.1%)
AHI ≥ 30 54 (14.4%)
Central AHI, events/h 1.1 (3.8)
DI4%, desaturations/h 10.5 (13.5)
DI3%, desaturation/h 15.9 (18.7)
Nadir SpO2 83.6 (8.96)
Nocturnal average SpO2 93.6 (3.84)
Tsat90% 6.1 (12.6)
Quantitative variables are tabulated as mean (SD).
TaBle 1 | Patient and cutaneous melanoma characteristics (n = 376).
Parameters N (%)
Patients, n (%) 376 (100%)
Gender, n (% males) 199 (52.9%)
Age (years) 56.4 (15.1)
BMI, kg/m2 27.3 (4.6)
skin phototype n (%)
I 13 (3.5%)
II 182 (48.4%)
III 159 (42.3%)
IV 22 (5.9%)
V 0 (0%)
Melanoma family history, n (%) 37 (9.8%)
Sun exposure >20 h/week, n (%) 121 (32.2%)
Breslow index (thickness in mm) 1.70 (2.5)
Ulceration, n (%) 65 (17.3%)
Regression, n (%) 91 (24.2%)
Mitotic rate (>5 mitotic cells/mm2), n (%) 55 (14.6%)
clark level, n (%)
I 2 (0.5%)
II 133 (35.4%)
III 130 (34.6%)
IV 99 (26.3%)
V 10 (2.7%)
subtype, n (%)
Superficial spreading melanoma 268 (71.3%)
Nodular melanoma 60 (16%)
Lentigo malignant melanoma 24 (6.4%)
Acral lentiginous melanoma 19 (5.1%)
Sentinel lymph node, n (%) 43 (11.4%)
anatomical site, n (%)
Head and neck 54 (14.4%)
Body 157 (41.8%)
Upper limb 55 (14.6%)
Lower limb 94 (25%)
Acral 15 (4%)
extension, n (%)
Local (I–II) 324 (86.2%)
Loco-regional (III) 42 (12.2%)
Distant metastasis (IV) 4 (0.9%)
Previous nevus, n (%) 104 (27.7%)
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statistical analysis
The SPSS 20.0 statistical package (Chicago, IL, USA) was used 
for all analyses. The data were expressed by using the mean and 
SD, or the median and the interquartile range for quantitative 
variables, according to whether or not they followed a normal 
distribution. The qualitative and dichotomic variables were 
expressed as the absolute value and the percentage with respect 
to the total. For analyses purposes, histochemical assessments 
of HIF-1α and VEGF expression variables were dichotomized: 
HIF-1α expression >6% (high expression) was compared with 
those samples with <6%, and VEGF expression >75% of cells was 
compared with those with <75%.
The comparison between these two groups’ baseline variables 
was made with the Student’s t-test for independent means or the 
Mann–Whitney test, according to the distribution of the quan-
titative variables, while the chi-square test was used to compare 
the two percentages. The factors independently related to the 
presence of a high HIF-1α or VEGF expressions were determined 
by introducing into two multivariate logistical regression analyses 
those variables which, in the opinion of the researchers, could 
have clinical importance. Odds ratios with 95% confidence 
intervals were calculated for each molecule expression. Although 
a two-tailed p-value of <0.05 was initially considered as indica-
tive of statistical significance, Bonferroni test was used to correct 
p-values for multiple comparisons as appropriate.
resUlTs
Baseline characteristics
Of 476 eligible patients, 443 were prospectively recruited and 
provided informed consent to participate in this study and finally, 
376 subjects had biopsy tissues available for analysis. The baseline 
clinical and tumor characteristics are depicted in Table  1, and 
the sleep-related symptoms and sleep test variables are shown in 
Table 2. The patients had a mean age of 56.4 (15.1) years (52.9% 
males), BMI of 27.3 (4.6) kg/m2, apnea–hypopnea index (AHI) 
of 14.9 (16.5) event/h, and DI4% of 10.2 (13.7) desaturations/h. 
Regarding the melanoma tumor, the mean Breslow index was 
1.70 (2.5) mm, the most common anatomical site was the body 
(41.8%), and only four patients had distant metastasis at the time 
of the diagnosis.
VegF and hiF-1α expression
The vast majority of melanoma samples presented high VEGF 
expression (333 patients, 88.8%), and non-high HIF-1α expres-
sion (360 patients, 95.7%). Only two samples (0.5%) presented 
no VEGF expression, and only 16 samples (4.2%) presented high 
HIF-1α expression, with only five patients presenting HIF-1α 
expression in more than 10% of cells. 6 (1.6%), 12 (3.4%), and 
TaBle 5 | Comparisons between the groups with high and low expression 
of hypoxia inducible factor (HIF)-1α regarding their general characteristics and 
aggressiveness markers of melanoma.
Variable hiF-1α high 
expression 
(n = 16)
hiF-1α non-high 
expression  
(n = 360)
p-Value
Age (years) 62.3 (15) 56.2 (15) 0.61
BMI (kg/m2) 27.8 (4.7) 27.3 (4.6) 0.86
Gender (% males) 56% 53% 0.38
Breslow index 5.53 (4.8) 1.53 (2.21) 0.0001
Ulceration 44% 16% 0.0001
Positive sentinel lymph 40% 10% 0.0001
Mitotic index (/mm2) 6.44 (7.9) 2.1 (3.8) 0.01
Clark index 3.7 (0.79) 2.9 (0.85) 0.65
Regression 25% 24% 0.90
Bold fond indicates p < 0.05.
TaBle 4 | Comparisons between expression groups of vascular endothelial 
growth factor (VEGF) regarding sleep-disordered breathing variables and 
intermittent/continuous hypoxia indicators.
Variable VegF high 
expression 
(n = 334)
VegF non-high 
expression  
(n = 42)
p-Value
Apnea–hypopnea index (/h) 14.6 (16) 15.8 (20) 0.058
DI4% (/h) 10 (13.2) 10.9 (16.6) 0.24
Mean SpO2 93.8 (1.97) 93.3 (2.08) 0.69
Nadir SpO2 83.5 (9.56) 83.8 (6.8) 0.38
Tsat <90% 5.4 (12.03) 8.68 (15.7) 0.012
Epworth score 6.12 (3.5) 5.7 (3.2) 0.67
Bold fond indicates p < 0.05.
TaBle 3 | Comparisons between expression of vascular endothelial growth 
factor (VEGF) and general characteristics and aggressiveness markers of 
melanoma.
Variable VegF high 
expression 
(n = 334)
VegF non-high 
expression  
(n = 42)
p-Value
Age (years) 56.3 (15.3) 57.4 (13.9) 0.21
BMI (kg/m2) 27.2 (4.6) 29.1 (3.8) 0.224
Gender (% males) 51% 62% 0.0001
Breslow index 1.67 (2.6) 1.89 (2.26) 0.59
Ulceration 17% 21% 0.19
Positive sentinel lymph 12% 12% 0.92
Mitotic index (/mm2) 2.19 (3.7) 3.46 (6.6) 0.006
Clark index 2.94 (0.86) 3.1 (0.85) 0.91
Regression 24% 24% 0.90
Bold fond indicates p < 0.05.
TaBle 8 | Logistic regression analysis showing the independent relationships 
between the Breslow index and DI4% values and the presence of high 
expression levels of hypoxia inducible factor-1α in cutaneous melanoma tumors.
Variable β coefficient se Odds ratio 95% ci p
Breslow index 0.24 0.068 1.28 1.18–1.46 0.0001
DI4% 0.33 0.098 1.03 1.01–1.06 0.001
DI4%; desaturation index at 4%.
p < 0.05.
TaBle 7 | Logistic regression analysis illustrating the lack of independent 
relationships between VEGF expression and melanoma aggressiveness, gender, 
and sleep study variables.
Variable β coefficient se Odds ratio 95% ci p-Value
Gender 0.21 0.329 1.24 0.65–2.35 0.52
AHI −0.004 0.01 0.99 0.98–1.02 0.68
Tsat90% −0.016 0.01 0.98 0.90–1.01 0.15
Mitotic index −0.047 0.03 0.95 0.90–1.01 0.12
AHI, apnea–hypopnea index; Tsat90%, night-time spent with oxyhemoglobin saturation 
below 90%.
TaBle 6 | Comparisons between the groups with high and low expression 
of hypoxia inducible factor (HIF)-1α in relation to sleep-disordered breathing 
variables and intermittent/continuous hypoxia indicators.
Variable hiF-1α high 
expression  
(n = 16)
hiF-1α non-high 
expression  
(n = 360)
p-Value
Apnea–hypopnea index (/h) 24.1 (17.8) 14.5 (16.3) 0.37
DI4% (/h) 18.8 (16.6) 9.8 (13.5) 0.081
Mean SpO2 93.5 (1.41) 93.8 (1.9) 0.153
Nadir SpO2 79.1 (12.8) 83.7 (9.1) 0.008
Tsat <90% 5.2 (6.8) 5.85 (12.7) 0.329
Epworth score 6.6 (3.3) 6.1 (3.6) 0.88
Bold fond indicates p < 0.05.
5
Almendros et al. IH Increases HIF-1α in CM
Frontiers in Neurology | www.frontiersin.org April 2018 | Volume 9 | Article 272
24 (6.4%) samples presented VEGF expression in less than 25%, 
between 25 and 50%, and between 51 and 75% of cells, respectively.
Univariate analysis
Those patients with CM and high VEGF expression were most 
frequently females and showed significantly less mitotic index 
(Table 3), higher AHI value (nearly statistically significant), and 
lower Tsat90 (Table 4).
On the other hand, those patients with CM and high HIF-1α 
expression showed significantly more CM aggressiveness mark-
ers, including increased mitotic index, higher Breslow index, the 
presence of ulceration and proportion of positive sentinel nodes 
(Table 5), and greater SDB severity regarding their correspond-
ing DI4% (near statistically significant association: p = 0.08) and 
nadir SpO2 values (Table 6).
Multivariate analysis: logistic 
regressions
To explore which variables were independently associated with 
high VEGF expression, four variables were introduced in the 
stepwise logistic regression: gender, AHI, Tsat90%, and mitotic 
index. However, none of these variables were significantly associ-
ated with VEGF expression (Table 7).
A similar analysis was conducted for HIF-1α expression. 
In this case, the two variables introduced into the logistic regres-
sion analysis were the Breslow index, which was the best marker 
of melanoma aggressiveness, and the DI4% as a marker of IH. 
Table 8 shows that both variables were independently associated 
with higher expression of HIF-1α.
DiscUssiOn
This study shows that levels of HIF-1α expression in CM are 
independently associated with indicators of episodic hypoxia as 
derived from nocturnal polygraphic recordings in a large pro-
spectively recruited cohort of CM patients. However, contrary 
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to the significant associations between the patterns of HIF-1α 
expression and the severity of sleep-disordered breathing, VEGF 
expression was high in the vast majority of CM lesions, and did 
not manifest any significant relationship with polygraphically 
derived measurements, suggesting the absence of co-linearity 
between HIF-1α and VEGF expression in CM.
Before we discuss the potential implications of our findings, 
several methodological points deserve mention. First, this is 
the first prospective study concurrently evaluating one type of 
cancer, namely CM, and the presence of sleep-disordered breath-
ing. Indeed, most of the existing literature to date has relied 
on retrospective databases, or alternatively, due to cohort size 
limitations, has not investigated a specific type of malignancy 
(28, 30, 35–41). The current study overcomes this major limita-
tion, even if the methodological approach for assessment of sleep- 
disordered breathing consisted of overnight polygraphy rather 
than polysomnography, such that the role of disrupted sleep can-
not be deduced (42). Of note, the prevalence of OSA and the dis-
tribution of severity categories of OSA in this cohort were similar 
to that reported in other population-based studies (43, 44), fur-
ther attesting to the overall absence of bias in patient recruitment, 
which as indicated was guided by the diagnosis of CM. Second, to 
minimize any potential bias, we ascertained that there would be 
complete separation in the processing of the polygraphy scoring 
and the classification of the aggressiveness CM markers by the 
various expert panels. Finally, we implemented highly stringent 
and blinded HIF-1α and VEGF immunohistochemistry staining 
and cell counting procedures. However, we opted for a straight-
forward assessment of the expression of HIF-1α and VEGF 
to establish the potential validity of the a  priori assumption, 
i.e., OSA is associated with increased hypoxia-related markers 
in CM tumors. In light of the current findings, future explora-
tion of the major cell lineage subsets in which the presence of 
OSA induces the increased expression of HIF-1α would be of 
potential interest to the understanding of the dynamic under-
pinnings regulating tumor growth and metastatic potential. We 
should also remark that the number of CM patients with very 
high expression of HIF-1α was small (n = 16) and reflects the 
quartile-based categorical stratification approach undertaken 
here, as dictated by statistical considerations. Indeed, expansion 
of the number of staining intensity categories such as to offer 
more refined analyses would have required a much large cohort 
size to achieve adequate statistical power.
Indeed, previous work has indicated that HIF-1α plays patho-
physiological roles in some of the previously identified morbid 
consequences of the disease. For example, the IH of OSA has been 
shown to contribute to liver fibrosis via recruitment of HIF-1α 
signaling (45). Similarly, targeting HIF-1α-related pathways 
may attenuate cardiovascular and metabolic consequences of IH 
(46–50). Thus, it is reasonable to assume that increased HIF-1α 
expression in the context of sleep-disordered breathing in our 
cohort would lead to increased HIF-1α expression in tissues 
in general and more specifically in the CM lesions, where its 
transcriptional activity could have fostered increased prolifera-
tion and other aggressiveness indicators (14–16). In contrast, the 
absence of any significant association between VEGF expression 
in the CM sections and correlates of nocturnal hypoxemia was 
surprising. Indeed, previous studies have shown that circulating 
levels of VEGF are increased in OSA (51–54), suggesting that 
similar patterns may be present in tissues. However, the pres-
ence of an unfavorable balance between VEGF and endothelial 
and vascular factors that may promote vascular injury has been 
suggested in OSA and could reduce the efficacy of the VEGF pro-
angiogenic activity (55). Alternatively, chronic IH may attenuate 
rather promote the transcription of HIF-1α at the promoter level 
of its gene targets as recently shown (50), such that the major 
driver for increased VEGF expression in the tumors could be 
the intrinsic intra-tumoral hypoxia rather than the IH of OSA. 
Under such circumstances, it is also possible that the increased 
VEGF expression may not necessarily reflect the severity of OSA 
or of intra-tumoral hypoxia, and may be driven by alternative 
transcriptional regulators such as HIF-2 (21). Notwithstanding, 
the presence of independent associations between a prognostic 
indicator of CM (i.e., Breslow index), and a measure of OSA 
severity (i.e., DI4%) as explaining the variance in HIF-1α expres-
sion abundance suggest that the presence of OSA and its severity 
may contribute to the malignant characteristics of CM, and play 
a deleterious role in the outcomes of this highly prevalent tumor.
cOnclUsiOn
In a large multicenter cohort of patients being diagnosed with 
CM, the expression of HIF-1α in the tumoral lesions is indepen-
dently associated with nocturnal IH measures of sleep disordered 
breathing severity. These findings provide additional support to 
the evolving epidemiological and biological evidence whereby 
sleep apnea may play a deleterious role in cancer outcomes.
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